This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Case Reports

. 2010 Aug;34(8):e197-9.

doi: 10.1016/j.leukres.2010.01.019. Epub 2010 Mar 7.

Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment

Hélène Monjanel, Christophe Hourioux, Flavie Arbion, Philippe Colombat, Séverine Lissandre, Marie Paule Regner, Delphine Senecal

PMID: 20211489
DOI: 10.1016/j.leukres.2010.01.019

Case Reports

Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment

Hélène Monjanel et al. Leuk Res. 2010 Aug.

. 2010 Aug;34(8):e197-9.

doi: 10.1016/j.leukres.2010.01.019. Epub 2010 Mar 7.

Authors

Hélène Monjanel, Christophe Hourioux, Flavie Arbion, Philippe Colombat, Séverine Lissandre, Marie Paule Regner, Delphine Senecal

PMID: 20211489
DOI: 10.1016/j.leukres.2010.01.019

No abstract available

PubMed Disclaimer

Similar articles

Efficacy and safety of long-term (>7 year) alemtuzumab therapy for refractory T-cell large granular lymphocytic leukaemia.
Olteanu H, Harrington AM, Ramirez S, Kroft SH, Hari P. Olteanu H, et al. Br J Haematol. 2010 Aug;150(4):480-1. doi: 10.1111/j.1365-2141.2010.08218.x. Epub 2010 Apr 28. Br J Haematol. 2010. PMID: 20456357 No abstract available.
Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A, Wierda WG, LaPushin R, O'Brien SM, Faderl S, Browning ML, Keating MJ. Ferrajoli A, et al. Eur J Haematol. 2008 Apr;80(4):296-8. doi: 10.1111/j.1600-0609.2007.01023.x. Epub 2007 Dec 21. Eur J Haematol. 2008. PMID: 18182081 Clinical Trial.
Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia.
Au WY, Lam CC, Chim CS, Pang AW, Kwong YL. Au WY, et al. Leuk Res. 2005 Oct;29(10):1213-5. doi: 10.1016/j.leukres.2005.02.018. Epub 2005 Apr 25. Leuk Res. 2005. PMID: 16111536
The role of alemtuzumab in the management of T-cell malignancies.
Dearden C. Dearden C. Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52. doi: 10.1053/j.seminoncol.2006.01.029. Semin Oncol. 2006. PMID: 16720203 Review.
Novel therapeutic strategies with alemtuzumab for chronic lymphocytic leukemia.
Rai KR. Rai KR. Semin Oncol. 2006 Apr;33(2 Suppl 5):S15-22. doi: 10.1053/j.seminoncol.2006.01.025. Semin Oncol. 2006. PMID: 16720199 Review.

See all similar articles

Cited by

Alemtuzumab for haematological malignancies.
An N, Bian K, Li C. An N, et al. Ann Hematol. 2025 May;104(5):2593-2603. doi: 10.1007/s00277-025-06344-8. Epub 2025 Apr 11. Ann Hematol. 2025. PMID: 40214729 Free PMC article. Review.
How I treat LGL leukemia.
Lamy T, Loughran TP Jr. Lamy T, et al. Blood. 2011 Mar 10;117(10):2764-74. doi: 10.1182/blood-2010-07-296962. Epub 2010 Dec 29. Blood. 2011. PMID: 21190991 Free PMC article.
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
Dumitriu B, Ito S, Feng X, Stephens N, Yunce M, Kajigaya S, Melenhorst JJ, Rios O, Scheinberg P, Chinian F, Keyvanfar K, Battiwalla M, Wu CO, Maric I, Xi L, Raffeld M, Muranski P, Townsley DM, Young NS, Barrett AJ, Scheinberg P. Dumitriu B, et al. Lancet Haematol. 2016 Jan;3(1):e22-9. doi: 10.1016/S2352-3026(15)00227-6. Epub 2015 Dec 17. Lancet Haematol. 2016. PMID: 26765645 Free PMC article. Clinical Trial.
The pathogenesis and treatment of large granular lymphocyte leukemia.
Steinway SN, LeBlanc F, Loughran TP Jr. Steinway SN, et al. Blood Rev. 2014 May;28(3):87-94. doi: 10.1016/j.blre.2014.02.001. Epub 2014 Mar 7. Blood Rev. 2014. PMID: 24679833 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science